Research letter
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B

https://doi.org/10.1016/j.jaad.2018.02.023Get rights and content

First page preview

First page preview
Click to open first page preview

References (5)

There are more references available in the full text version of this article.

Cited by (53)

  • Vitiligo: An immune disease and its emerging mesenchymal stem cell therapy paradigm

    2023, Transplant Immunology
    Citation Excerpt :

    These effects lead to the recruitment of CD8+ CTLs in skin lesions for secondary damage to melanocytes [81]. Numerous studies reported that JAK inhibitors can inhibit the IFN-γ-dependent JAK/STAT pathway to reduce IFN-γ and the secretion of CXCL9 and CXCL10, thereby reducing the damage caused by CD8+ CTLs to melanocytes [82–86]. In addition, in skin lesions of patients with vitiligo, JAK1 and JAK3 were highly expressed.

  • Vitiligo Skin T Cells Are Prone to Produce Type 1 and Type 2 Cytokines to Induce Melanocyte Dysfunction and Epidermal Inflammatory Response Through Jak Signaling

    2022, Journal of Investigative Dermatology
    Citation Excerpt :

    Emerging treatments mainly rely on targeting the immune system (Migayron et al., 2020). In this context, Jak inhibitors have shown promising results in clinical trials (Craiglow and King, 2015; Harris et al., 2016; Joshipura et al., 2018; Liu et al., 2017; Olsen et al., 2020; Rothstein et al., 2017). Their efficacy is attributed to the targeting of immune cells, including T cells, and to the inhibition of IFN-γ signaling (Frisoli et al., 2020).

  • Janus kinase inhibitors in dermatology: Part II. A comprehensive review

    2022, Journal of the American Academy of Dermatology
    Citation Excerpt :

    Moreover, when treating vitiligo with JAK inhibitors, concomitant light exposure may enhance the treatment response, as JAK inhibitors are thought to suppress T-cell-mediated melanocyte destruction, while light therapy stimulates melanocyte regeneration.18 A number of studies have shown promise for the use of JAK inhibitors in the treatment of vitiligo (Table III).19-24 Environmental exposure, genetic predisposition, and immunologic mechanisms underly the pathogenesis of sarcoidosis.

View all citing articles on Scopus

Funding sources: None.

Conflicts of interest: Dr Rosmarin has served on advisory boards or is a consultant to Pfizer, Eli Lilly, Abbvie, Janssen, Regeneron, Sanofi, Celgene, and Novartis. Dr Rosmarin also serves as an investigator for Incyte. Other authors do not have disclosures to report.

View full text